Financials

v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 11,037 $ 17,116
Prepaid expenses and other current assets 606 827
Total Current Assets 11,643 17,943
Property and equipment, net 801 872
Deposits and other assets 23 23
Total Assets 12,467 18,838
Current Liabilities:    
Accounts payable 1,493 2,020
Accrued expenses 1,058 1,526
Warrant liabilities 1,428 4,083
Accrued employee benefits 1,016 2,074
Deferred rent 92 90
Total Current Liabilities 5,087 9,793
Long term deferred rent 377 402
Total Liabilities 5,464 10,195
Stockholders' Deficit:    
Common stock, $0.001 par value; 350,000,000 shares authorized, 128,648,365 issued and 128,566,886 outstanding 129 129
Additional paid-in capital 193,230 192,545
Accumulated deficit (196,545) (194,170)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit (3,186) (1,496)
Non-controlling interest (1,923) (1,914)
Total Stockholders' Deficit: (5,109) (3,410)
Total Liabilities and Stockholders' Deficit 12,467 18,838
Series A Preferred Stock [Member]    
Current Liabilities:    
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized,120,000 issued and outstanding $ 12,112 $ 12,053

Source

v3.8.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Operating Costs and Expenses:    
General and administrative $ 1,620 $ 2,090
Research and development 3,370 6,059
Total Operating Costs and Expenses 4,990 8,149
Loss from Operations (4,990) (8,149)
Other Income:    
Change in fair value of warrant liability 2,655 5,090
Interest income 9 1
Total Other Income 2,664 5,091
Net Loss (2,326) (3,058)
Net Loss Attributable to Non-controlling Interest (10) (212)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (2,316) (2,846)
Series A Preferred Stock Dividends (59) 0
Net Loss Attributable to Common Stock Holders $ (2,375) $ (2,846)
Net Loss Per Share - Basic and Dilutive $ (0.02) $ (0.02)
Weighted average number of shares outstanding during the period - Basic and Dilutive 128,566,883 117,447,260

Source

v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash Flows From Operating Activities:    
Net Loss $ (2,326) $ (3,058)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 676 1,135
Warrant issued to consultant 9 0
Change in fair value of warrant liabilities (2,655) (5,090)
Depreciation 71 57
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 221 (851)
Accounts payable (527) 1,803
Accrued expenses (468) (493)
Accrued employee benefits (1,058) 474
Deferred rent (22) 15
Net Cash Used In Operating Activities (6,079) (6,008)
Cash Flows From Investing Activities:    
Purchases of property and equipment 0 (11)
Net Cash Used In Investing Activities 0 (11)
Cash Flows From Financing Activities:    
Proceeds from issuance of common stock for stock option exercises 0 166
Proceeds from "at the market" stock issuance 0 269
Net Cash Provided By Financing Activities 0 435
Net decrease in cash (6,079) (5,584)
Cash at beginning of period 17,116 19,055
Cash at end of period $ 11,037 $ 13,471

Source